Bottom irregularities in the North-SeaRICHTER K; SCHMALFELDT B; SIEBERT J et al.Deutsche hydrographische Zeitschrift. 1976, Vol 29, Num 1, pp 1-10Article

SCHALLGESCHWINDIGKEIT UND IMPEDANZ DES OBEREN MEERES BODENS IN GEBIETEN DER NORDSEE, DES SKAGERRAKS, DES KATTEGATS UND DER OSTSEE = LA VITESSE DU SON ET L'IMPEDANCE EN SURFACE DU FOND DE LA MER DANS LA MER DU NORD, LE SKAGERRAK, LE KATTEGAT ET LA BALTIQUESCHIRMER F; SCHMALFELDT B; SIEBERT J et al.1979; DTSCHE HYDROGR. Z.; DEU; DA. 1979; VOL. 32; NO 6; PP. 279-288; ABS. ENG/FRE; BIBL. 5 REF.Article

BOTTOM IRREGULARITIES IN THE NORTH SEA.RICHTER K; SCHMALFELDT B; SIEBERT J et al.1976; DTSCHE HYDROGR. Z.; DTSCH.; DA. 1976; VOL. 29; NO 1; PP. 1-10; ABS. ALLEM. FR.; BIBL. 5 REF.Article

SCHALLGESCHWINDIGKEIT UND IMPEDANZ DES OBEREN MEERESBODENS IN GEBIETEN DER NORDSEE, DES SKAGERRAKS, DES KATTEGATS UND DER OSTSEE = VITESSE DU SON ET IMPEDANCE DE LA COUCHE SUPERFICIELLE DU SOL MARIN DANS LES ZONES DE LA MER DU NORD, DU SKAGERRAK, DU KATTEGATS ET DE LA BALTIQUESCHIRMER F; SCHMALFELDT B; SIEBERT J et al.1979; DTSCHE HYDROGR. Z.; DEU; DA. 1979; VOL. 32; NO 6; PP. 279-288; ABS. FRE/ENG; BIBL. 3 REF.; 5 ILL.Article

Die septische Ovarialvenenthrombose (POVT) : Konservatives Management mit CT-geführter Verlaufskontrolle = Puerperal ovarian vein thrombosis (POVT) conservative management with CT-guided follow-up monitoringKUHN, W; SCHMALFELDT, B; LENZ, M et al.Geburtshilfe und Frauenheilkunde. 1995, Vol 55, Num 5, pp 287-289, issn 0016-5751Article

The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patientsBLECHSCHMIDT, K; SASSEN, S; SCHMALFELDT, B et al.British journal of cancer. 2008, Vol 98, Num 2, pp 489-495, issn 0007-0920, 7 p.Article

Stromelysin-3 expression in invasive ovarian carcinomas and tumours of low malignant potentialMUELLER, J; BREBECK, B; SCHMALFELDT, B et al.Virchows Archiv. 2000, Vol 437, Num 6, pp 618-624, issn 0945-6317Article

Die intravenöse oder orale Etoposid-Therapie des Platin-refraktären Ovarialkarzinom-Frührezidivs : Ergebnisse einer prospektiven randomisierten Studies = Oral and parenteral etoposide in platinum refractory ovarian cancer patients : Results of a prospective randomised studyKUHN, W; SCHMALFELDT, B; DOSE, J et al.Geburtshilfe und Frauenheilkunde. 1996, Vol 56, Num 2, pp 105-110, issn 0016-5751Article

Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancerDORN, J; HARBECK, N; KATES, R et al.Annals of oncology. 2011, Vol 22, Num 4, pp 877-883, issn 0923-7534, 7 p.Article

Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2SCHMALFELDT, B; KUHN, W; REUNING, U et al.Cancer research (Baltimore). 1995, Vol 55, Num 18, pp 3958-3963, issn 0008-5472Article

Ovarialkarzinom - : ist die Intraperitoneale Therapie wirklich neuer Standard? = Can intraperitoneal chemotherapy be regarded as a new standard in advanced ovarian cancer?DU BOIS, A; SCHMALFELDT, B; MEIER, W et al.Geburtshilfe und Frauenheilkunde. 2006, Vol 66, Num 5, pp 490-494, issn 0016-5751, 5 p.Article

Non-enrolment of ovarian cancer patients in clinical trials : reasons and backgroundHATTER, P; DU BOIS, A; SCHADE-BRITTINGER, C et al.Annals of oncology. 2005, Vol 16, Num 11, pp 1801-1805, issn 0923-7534, 5 p.Article

Pegylated liposomal doxorubicin (CAELYX^®) in patients with advanced ovarian cancer: results of a German multicenter observational studySEHOULI, Jalid; CAMARA, O; SCHMIDT, M et al.Cancer chemotherapy and pharmacology. 2009, Vol 64, Num 3, pp 585-591, issn 0344-5704, 7 p.Article

Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer : results of a multicenter phase-II trialSEHOULI, J; OSKAY-ÖZCELIK, G; LICHTENEGGER, W et al.Annals of oncology. 2006, Vol 17, Num 6, pp 957-961, issn 0923-7534, 5 p.Article

Entwicklungen in der Therapie des fortgeschrittenen Ovarialkarzinoms FIGO III = Development in the therapy of the advanced ovarian cancer FIGO IIIKUHN, W; JÄNICKE, F; GRAEFF, H et al.Geburtshilfe und Frauenheilkunde. 1993, Vol 53, Num 5, pp 293-302, issn 0016-5751, 10 p.Article

Disease-adapted relapse therapy for ovarian cancer : Results of a prospective studyKUHN, W; SCHMALFELDT, B; TILCH, G et al.International journal of oncology. 1998, Vol 13, Num 1, pp 57-63, issn 1019-6439Article

Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT studyTRILLSCH, F; MAHNER, S; HILPERT, F et al.Annals of oncology. 2014, Vol 25, Num 7, pp 1320-1327, issn 0923-7534, 8 p.Article